Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cyclo Therapeutics Inc (CYTH)

Cyclo Therapeutics Inc (CYTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,391
  • Shares Outstanding, K 28,768
  • Annual Sales, $ 1,080 K
  • Annual Income, $ -20,060 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta -0.38
  • Price/Sales 18.21
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.85
  • Most Recent Earnings $-0.26 on 11/14/24
  • Next Earnings Date 11/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.20
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +17.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6147 +11.84%
on 11/14/24
0.8200 -16.16%
on 10/22/24
-0.1225 (-15.12%)
since 10/21/24
3-Month
0.5946 +15.62%
on 09/12/24
0.9845 -30.17%
on 08/22/24
-0.5725 (-45.44%)
since 08/21/24
52-Week
0.5946 +15.62%
on 09/12/24
2.1150 -67.49%
on 01/26/24
-0.5525 (-44.56%)
since 11/21/23

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPLK, CYTH, AMTI, EBC

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SPLK : 156.90 (+0.25%)
CYTH : 0.6875 (-3.01%)
AMTI : 0.2630 (-14.30%)
EBC : 18.69 (+1.74%)
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation...

CYTH : 0.6875 (-3.01%)
RFL : 2.0000 (+2.56%)
Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation...

CYTH : 0.6875 (-3.01%)
Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation...

CYTH : 0.6875 (-3.01%)
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation...

CYTH : 0.6875 (-3.01%)
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation...

CYTH : 0.6875 (-3.01%)
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation...

CYTH : 0.6875 (-3.01%)
Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for...

CYTH : 0.6875 (-3.01%)
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation...

CYTH : 0.6875 (-3.01%)
Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for...

CYTH : 0.6875 (-3.01%)

Business Summary

Cyclo Therapeutics Inc. is a clinical-stage biotechnology company. It develops cyclodextrin-based products for the treatment of disease. The company's Trappsol(R) Cyclo(TM), an orphan drug designated product primarily in the United States and Europe, is in ongoing formal clinical trials for Niemann-Pick...

See More

Key Turning Points

3rd Resistance Point 0.7359
2nd Resistance Point 0.7229
1st Resistance Point 0.7159
Last Price 0.6875
1st Support Level 0.6959
2nd Support Level 0.6829
3rd Support Level 0.6759

See More

52-Week High 2.1150
Fibonacci 61.8% 1.5342
Fibonacci 50% 1.3548
Fibonacci 38.2% 1.1754
Last Price 0.6875
52-Week Low 0.5946

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar